An observational study in Heart Failure, sponsored by Future University in Egypt. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by Future University in Egypt · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Heart Failure with a site in Egypt — 16 open to participants now, 21 under way, 2 of them phase 3. Heart Failure · Egypt.
Among the 63 studies in Heart Failure with a site in Egypt, this one is the 9th largest by planned enrollment of the 17 observational ones that give a count, is one of 11 that started in 2026, is one of 17 observational ones, reaches primary completion later than 7 of the 20 other live ones, and was the 51st registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →16 of the 63 studies in Heart Failure with a site in Egypt are open now. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 45–65
Tanta University · Sites in Egypt
Ages 18+
Cairo University · Sites in Egypt
Ages 18+
Ain Shams University · Sites in Egypt
Ages 1 mo–18 yrs
Kafrelsheikh University · Sites in Egypt
Ages 18+
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 6 · Phase 4 12
First in 2014; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is below the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 68 across the 46 interventional studies, 140 across the 17 observational. Of the 33 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 63 have an industry lead sponsor. The 10 most frequent:
Future University in Egypt is the lead sponsor of 105 studies on the registry; 32 are open to participants now.
Future University in Egypt has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
6 of the studies in Heart Failure with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07841665Alexandria UniversityAI-Based Personalized Self-Management for Patients With Heart Failure | 2026-12 |
| NCT07692256Ain Shams Universitythe Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients | 2026-12-01 |
| NCT07372040Tanta UniversityAdd-on Diuretics in Acute Decompensated Heart Failure | 2027-02-01 |
| NCT07930390Alexandria UniversityHandheld Fan Direction for Breathlessness in Chronic Heart and Lung Disease | 2027-02-03 |
| NCT07394270German University in CairoEffect of Add-on L-Arginine Therapy on Heart Failure Patients | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 63 studies in Heart Failure with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study looks at people with heart failure who are admitted to the hospital. The goal of the study is to understand whether taking a heart failure medicine called angiotensin receptor-neprilysin inhibitor (ARNI) before hospital admission affects short-term health outcomes.
The study will compare two groups of participants: those who were already taking ARNI before coming to the hospital and those who were not. Information will be collected from medical records during the hospital stay, including heart-related events, kidney-related events, and how long participants stay in the hospital.
Some participants will also be followed for a short period after discharge. This study may help improve understanding of outcomes associated with ARNI use in people with heart failure in routine clinical care.
The study population consists of adult patients with heart failure and reduced ejection fraction who are admitted to the cardiology wards at Mansoura University Hospital (MUH) during the study period. Participants include those who were already receiving ARNI therapy prior to hospital admission and those who were not, representing typical patients seen in clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Prehospital ARNI use
Other: No prehospital ARNI use
Participants who were using ARNI therapy before hospital admission
Participants who were not using ARNI therapy before hospital admission
In-hospital cardiac and renal events
Time frame: 3 months
NYHA classification
Time frame: 3 months
Start is estimated for Jan 2026; primary completion for Apr 2026, 3 months later.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 3 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.